Article in eLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Natasha M Flores *Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States.
Geoffrey C FoxCurriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, United States.ORCID https://orcid.org/0000-0001-5898-0847
Hanyang DongDepartment of Biology, Stanford University, Stanford, United States.
Metehan CebeciDepartment of Biology, Stanford University, Stanford, United States.
Simone HausmannDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States.
Tourkian ChasanDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States.ORCID https://orcid.org/0000-0001-9108-2205
Jill M DowenCurriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, United States.
Brian D StrahlCurriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, United States.ORCID https://orcid.org/0000-0002-4947-6259
Pawel K MazurDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States.
Mechanisms of chromatin and transcriptional regulationR35GM126900 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Brian D Strahl · 2018 to 2026
$5.5M
NRSA in GeneticsT32GM135128 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Daniel J McKay, JEFF J. SEKELSKY · 2020 to 2026
$5.1M
Function of Protein Methylation in Chromatin and Signaling RegulationR35GM139569 · NIGMS · STANFORD UNIVERSITY · PI Or P. Gozani · 2021 to 2026
$4.0M
Tumor cell lineage diversity and composition in gastric cancer progression and therapy resistanceR01CA266280 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Pawel K. Mazur, Linghua Wang · 2022 to 2026
$3.2M
Therapeutic Targeting of NSD2 in Lung AdenocarcinomaR01CA272844 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Or P. Gozani, Pawel K. Mazur · 2023 to 2026
$2.6M
Mechanisms of action and therapeutic targeting of the CARM1-NFIB axis in small cell lung cancerR01CA272843 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MARK T. BEDFORD, Pawel K. Mazur · 2023 to 2026
$2.6M
Role of NSD3 in regulation of cancer pathogenesisR01CA278940 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Or P. Gozani, Pawel K. Mazur · 2023 to 2026
$2.6M
Role of SETD5 in Chromatin Regulation and TumorigenesisR01CA236949 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MAZUR, PAWEL K. · 2019 to 2023
$1.9M
The role of genome folding in regulating gene expression and chromatin stateR35GM152103 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Jill Dowen · 2024 to 2026
$1.3M
CPRIT Scholar in Cancer Research RR160078DOD Peer Reviewed Cancer Research Program CA181486DOD Peer Reviewed Cancer Research Program RP220391NCI NIH HHS R01 CA236949NCI NIH HHS R01 CA266280NCI NIH HHS R01 CA272843NCI NIH HHS R01 CA272844NCI NIH HHS R01 CA278940NCI NIH HHS RO1CA236949NCI NIH HHS RO1CA266280NCI NIH HHS RO1CA272843NCI NIH HHS RO1CA272844NCI NIH HHS RO1CA278940NIGMS NIH HHS R35 GM126900NIGMS NIH HHS R35GM126900NIGMS NIH HHS R35 GM139569NIGMS NIH HHS R35GM139569NIGMS NIH HHS R35 GM152103NIGMS NIH HHS R35GM152103NIGMS NIH HHS T32 GM135128NIGMS NIH HHS T32GM135128
6 · The paper itself
Abstract
Histone H3 trimethylation at lysine 36 (H3K36me3) is a key chromatin modification that regulates fundamental physiological and pathological processes. In humans, SETD2 is the only known enzyme that catalyzes H3K36me3 in somatic cells and is implicated in tumor suppression across multiple cancer types. While there is considerable crosstalk between the SETD2-H3K36me3 axis and other epigenetic modifications, much remains to be understood. Here, we show that Setd2 functions as a potent tumor suppressor in a KRAS
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
SETD2 suppresses tumorigenesis in a KRAS · full record | OpenQuestion